| NCT01218516 |
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung |
https://ClinicalTrials.gov/show/NCT01218516 |
Completed |
Morphotek |
2012-12-31 |
| NCT03380468 |
Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT03380468 |
Recruiting |
Fudan University |
2021-01-01 |
| NCT03298763 |
Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer |
https://ClinicalTrials.gov/show/NCT03298763 |
Recruiting |
University College, London |
2023-09-01 |
| NCT03184571 |
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC |
https://ClinicalTrials.gov/show/NCT03184571 |
Recruiting |
BerGenBio ASA |
2022-12-31 |
| NCT03110978 |
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT03110978 |
Recruiting |
M.D. Anderson Cancer Center |
2022-06-30 |
| NCT03076164 |
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib |
https://ClinicalTrials.gov/show/NCT03076164 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT03054298 |
CAR T Cells in Mesothelin Expressing Cancers |
https://ClinicalTrials.gov/show/NCT03054298 |
Recruiting |
University of Pennsylvania |
2021-03-31 |
| NCT03044626 |
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC |
https://ClinicalTrials.gov/show/NCT03044626 |
Active, not recruiting |
AIO-Studien-gGmbH |
2020-12-31 |
| NCT02979821 |
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) |
https://ClinicalTrials.gov/show/NCT02979821 |
Completed |
Korean Association for the Study of Targeted Therapy |
2017-12-31 |
| NCT02971176 |
Low-dose Protocol for Computed Tomography-guided Lung Biopsy |
https://ClinicalTrials.gov/show/NCT02971176 |
Completed |
Xuzhou Central Hospital |
2019-05-31 |
| NCT02929693 |
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02929693 |
Enrolling by invitation |
Shanghai University of Traditional Chinese Medicine |
2019-06-30 |
| NCT02893332 |
Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) |
https://ClinicalTrials.gov/show/NCT02893332 |
Recruiting |
Sichuan Provincial People’s Hospital |
2019-12-31 |
| NCT02889692 |
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02889692 |
Completed |
Shanghai University of Traditional Chinese Medicine |
2016-12-30 |
| NCT02759835 |
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib |
https://ClinicalTrials.gov/show/NCT02759835 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2021-02-01 |
| NCT02679443 |
Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT02679443 |
Completed |
Postgraduate Institute of Medical Education and Research |
2016-12-31 |
| NCT02668393 |
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02668393 |
Completed |
Boehringer Ingelheim |
2019-11-27 |
| NCT02834013 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
https://ClinicalTrials.gov/show/NCT02834013 |
Recruiting |
National Cancer Institute (NCI) |
2021-08-31 |
| NCT02194738 |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
https://ClinicalTrials.gov/show/NCT02194738 |
Recruiting |
National Cancer Institute (NCI) |
2021-09-28 |
| NCT03391869 |
Phase III Trial of (LCT) After Nivolumab and Ipilimumab |
https://ClinicalTrials.gov/show/NCT03391869 |
Recruiting |
M.D. Anderson Cancer Center |
2022-12-31 |
| NCT02535325 |
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT02535325 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-01-01 |
| NCT02513667 |
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02513667 |
Active, not recruiting |
University of Texas Southwestern Medical Center |
2020-08-31 |
| NCT02493582 |
The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR |
https://ClinicalTrials.gov/show/NCT02493582 |
Active, not recruiting |
The First People’s Hospital of Changzhou |
2030-07-31 |
| NCT02450591 |
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations |
https://ClinicalTrials.gov/show/NCT02450591 |
Completed |
Memorial Sloan Kettering Cancer Center |
2017-12-11 |
| NCT02303977 |
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT02303977 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2020-12-31 |
| NCT02281708 |
Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT02281708 |
Recruiting |
Seoul National University Hospital |
2018-09-30 |
| NCT02276027 |
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT02276027 |
Completed |
Novartis |
2019-10-15 |
| NCT02186847 |
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT02186847 |
Active, not recruiting |
NRG Oncology |
2019-04-16 |
| NCT02155465 |
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib |
https://ClinicalTrials.gov/show/NCT02155465 |
Completed |
Memorial Sloan Kettering Cancer Center |
2017-10-31 |
| NCT02120807 |
Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas |
https://ClinicalTrials.gov/show/NCT02120807 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-30 |
| NCT01294306 |
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy |
https://ClinicalTrials.gov/show/NCT01294306 |
Completed |
National Cancer Institute (NCI) |
2015-08-31 |
| NCT02737774 |
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation |
https://ClinicalTrials.gov/show/NCT02737774 |
Active, not recruiting |
Henan Cancer Hospital |
2019-10-25 |
| NCT03351842 |
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% |
https://ClinicalTrials.gov/show/NCT03351842 |
Recruiting |
Shanghai Pulmonary Hospital, Shanghai, China |
2019-09-01 |
| NCT01946100 |
Treatment of Multifocal Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT01946100 |
Active, not recruiting |
Mayo Clinic |
2020-10-31 |
| NCT01935336 |
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers |
https://ClinicalTrials.gov/show/NCT01935336 |
Active, not recruiting |
University of Colorado, Denver |
2017-01-31 |
| NCT01877083 |
Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung |
https://ClinicalTrials.gov/show/NCT01877083 |
Completed |
Eisai Inc. |
2016-02-03 |
| NCT01851096 |
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT01851096 |
Completed |
Esanex Inc. |
2015-10-31 |
| NCT01829217 |
Sunitinib in Never-Smokers With Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT01829217 |
Completed |
Dana-Farber Cancer Institute |
2017-08-31 |
| NCT01737502 |
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT01737502 |
Recruiting |
Mayo Clinic |
2020-08-21 |
| NCT01726296 |
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care |
https://ClinicalTrials.gov/show/NCT01726296 |
Completed |
Fox Chase Cancer Center |
2015-07-31 |
| NCT01719536 |
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients |
https://ClinicalTrials.gov/show/NCT01719536 |
Completed |
Betta Pharmaceuticals Co., Ltd. |
2016-09-30 |
| NCT01668823 |
Photodynamic Therapy in Treating Patients With Lung Cancer |
https://ClinicalTrials.gov/show/NCT01668823 |
Completed |
Roswell Park Cancer Institute |
2013-06-30 |
| NCT01588704 |
Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT01588704 |
Completed |
Sun Yat-sen University |
2014-01-31 |
| NCT01565538 |
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT01565538 |
Completed |
Sun Yat-sen University |
2012-05-31 |
| NCT01561456 |
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung |
https://ClinicalTrials.gov/show/NCT01561456 |
Completed |
Axelar AB |
2013-12-31 |
| NCT01557959 |
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT01557959 |
Completed |
Wake Forest University Health Sciences |
2011-02-28 |
| NCT01466660 |
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung |
https://ClinicalTrials.gov/show/NCT01466660 |
Completed |
Boehringer Ingelheim |
2016-04-08 |
| NCT01386385 |
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT01386385 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-01-02 |
| NCT01362790 |
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma |
https://ClinicalTrials.gov/show/NCT01362790 |
Completed |
National Institutes of Health Clinical Center (CC) |
2016-08-03 |
| NCT01345851 |
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT01345851 |
Active, not recruiting |
Jonsson Comprehensive Cancer Center |
2020-12-31 |
| NCT04344795 |
Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors |
https://ClinicalTrials.gov/show/NCT04344795 |
Recruiting |
Tempest Therapeutics |
2021-08-31 |
| NCT04046614 |
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology |
https://ClinicalTrials.gov/show/NCT04046614 |
Recruiting |
AIO-Studien-gGmbH |
2021-07-03 |
| NCT04027946 |
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
https://ClinicalTrials.gov/show/NCT04027946 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-04-30 |
| NCT03905317 |
Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene |
https://ClinicalTrials.gov/show/NCT03905317 |
Recruiting |
Sun Yat-sen University |
2022-02-28 |
| NCT03904563 |
Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT03904563 |
Recruiting |
Sun Yat-sen University |
2021-12-31 |
| NCT03891173 |
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT03891173 |
Recruiting |
Helix BioPharma Corporation |
2021-06-30 |
| NCT03704870 |
Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection |
https://ClinicalTrials.gov/show/NCT03704870 |
Completed |
University Health Network, Toronto |
2019-12-31 |
| NCT03696212 |
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT03696212 |
Recruiting |
Arrys Therapeutics |
2020-09-30 |
| NCT03676192 |
To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT03676192 |
Recruiting |
Celltrion |
2021-01-31 |
| NCT03662477 |
Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation |
https://ClinicalTrials.gov/show/NCT03662477 |
Recruiting |
Shenzhen Fifth People’s Hospital |
2019-12-20 |
| NCT03544814 |
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression |
https://ClinicalTrials.gov/show/NCT03544814 |
Completed |
Shanghai Chest Hospital |
2017-06-01 |
| NCT03476681 |
QUILT-3.017: Study of NEO-201 in Solid Tumors |
https://ClinicalTrials.gov/show/NCT03476681 |
Recruiting |
Precision Biologics, Inc |
2020-10-15 |
| NCT01259089 |
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT01259089 |
Completed |
Northwestern University |
2013-06-04 |
| NCT01051934 |
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT01051934 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-09-28 |
| NCT01003899 |
A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR] |
https://ClinicalTrials.gov/show/NCT01003899 |
Completed |
Boehringer Ingelheim |
2011-11-30 |
| NCT00966914 |
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin |
https://ClinicalTrials.gov/show/NCT00966914 |
Completed |
BioNumerik Pharmaceuticals, Inc. |
2013-04-30 |
| NCT00946712 |
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00946712 |
Active, not recruiting |
Southwest Oncology Group |
2017-08-31 |
| NCT03845296 |
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) |
https://ClinicalTrials.gov/show/NCT03845296 |
Recruiting |
Southwest Oncology Group |
2021-07-01 |
| NCT03199651 |
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT03199651 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-06-30 |
| NCT03345810 |
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) |
https://ClinicalTrials.gov/show/NCT03345810 |
Recruiting |
AIO-Studien-gGmbH |
2022-06-30 |
| NCT01609543 |
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations |
https://ClinicalTrials.gov/show/NCT01609543 |
Completed |
Hoffmann-La Roche |
2015-01-31 |
| NCT01578668 |
Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases |
https://ClinicalTrials.gov/show/NCT01578668 |
Completed |
Guangzhou Medical University |
2015-01-31 |
| NCT00716456 |
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed “Acquired Resistance” to Erlotinib |
https://ClinicalTrials.gov/show/NCT00716456 |
Completed |
Memorial Sloan Kettering Cancer Center |
2011-05-31 |
| NCT00511485 |
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) |
https://ClinicalTrials.gov/show/NCT00511485 |
Completed |
Endocyte |
2009-07-31 |
| NCT00456716 |
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT00456716 |
Completed |
Swedish Medical Center |
2008-12-31 |
| NCT00430261 |
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT00430261 |
Completed |
Swedish Medical Center |
2010-10-31 |
| NCT00368992 |
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00368992 |
Completed |
National Cancer Institute (NCI) |
2010-10-31 |
| NCT00334815 |
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00334815 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-07-01 |
| NCT00284141 |
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma |
https://ClinicalTrials.gov/show/NCT00284141 |
Completed |
Sanofi |
2008-07-31 |
| NCT00198380 |
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature |
https://ClinicalTrials.gov/show/NCT00198380 |
Completed |
Intergroupe Francophone de Cancerologie Thoracique |
2008-12-31 |
| NCT00137839 |
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung |
https://ClinicalTrials.gov/show/NCT00137839 |
Completed |
Dana-Farber Cancer Institute |
2008-11-30 |
| NCT00126581 |
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00126581 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00118183 |
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00118183 |
Completed |
National Cancer Institute (NCI) |
2007-04-30 |
| NCT00118144 |
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer |
https://ClinicalTrials.gov/show/NCT00118144 |
Completed |
National Cancer Institute (NCI) |
2010-12-31 |
| NCT00087412 |
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00087412 |
Completed |
National Cancer Institute (NCI) |
2007-07-31 |
| NCT00073398 |
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00073398 |
Completed |
Lumos Pharma |
2012-11-30 |
| NCT00049543 |
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00049543 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00040794 |
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00040794 |
Completed |
National Cancer Institute (NCI) |
2006-03-31 |
| NCT00021060 |
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00021060 |
Completed |
National Cancer Institute (NCI) |
2006-09-30 |
| NCT00020709 |
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00020709 |
Completed |
National Cancer Institute (NCI) |
2007-02-28 |
| NCT00005838 |
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00005838 |
Completed |
National Cancer Institute (NCI) |
2007-02-28 |
| NCT00002852 |
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT00002852 |
Completed |
National Cancer Institute (NCI) |
2004-07-31 |
| NCT00818441 |
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung |
https://ClinicalTrials.gov/show/NCT00818441 |
Completed |
Pfizer |
2012-04-27 |